Noradrenalin Zentiva (Norepinephrine)

Norepinephrine stimulates alpha‑1 receptors, causing peripheral blood vessels to constrict, and beta‑1 receptors, increasing heart muscle contractility and rate. This dual action elevates systemic vascular resistance and cardiac output, helping restore adequate perfusion in shock.

The dose is individualized by the prescribing clinician based on the patient’s hemodynamic status, target blood pressure, and response to therapy. Dosing is adjusted continuously during infusion under intensive monitoring.

The pregnancy category for norepinephrine is unknown. It should be used only if the potential benefit justifies any potential risk to the fetus, and breastfeeding decisions should be made in consultation with a healthcare professional.

Submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required), and import documentation.

The primary alternative vasopressor is phenylephrine, which acts mainly on alpha‑1 receptors and lacks beta‑1 activity. Norepinephrine provides both vasoconstriction and modest cardiac stimulation, making it preferred for most shock states where maintaining cardiac output is important.

The product must be stored refrigerated at 2‑8 °C, protected from light, and never frozen. Before use, inspect the vial for particulate matter and ensure it is at room temperature if required for infusion preparation.

It is given as an intravenous infusion, typically through a central or large peripheral line. The solution is diluted in compatible fluid and infused at a rate titrated to achieve the desired blood pressure response, with continuous monitoring.

Serious risks include severe hypertension, cardiac arrhythmias such as ventricular tachycardia, and myocardial ischemia. Prompt recognition and adjustment of the infusion rate are essential to mitigate these potentially life‑threatening events.

Patients with known hypersensitivity to norepinephrine or any of its excipients should not receive the product. Caution is also advised in individuals with uncontrolled tachyarrhythmias, severe peripheral vascular disease, or those receiving MAO inhibitors.